Biotech · Private company
Protalix
Track this companyFree. Adds Protalix to your Dealase workspace and tells you when its record changes.
Clinical trials61 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- agalsidase betaPhase 3 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Pegunigalsidase alfaPhase 3 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PRX-102 (pegunigalsidase alfa)Phase 3 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Methotrexate (MTX)Phase 2 · GoutClinicalTrials.gov · fetched Nov 12, 2026
- PRX-102Phase 2 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PRX-115Phase 2 · GoutClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)PHASE2 · RECRUITING · started Dec 22, 2025ClinicalTrials.gov NCT07280156 · fetched Nov 12, 2026
- Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly InfusionCOMPLETED · started Jan 26, 2022ClinicalTrials.gov NCT05186324 · fetched Nov 12, 2026
- Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 WeeksPHASE3 · COMPLETED · started Jul 10, 2017ClinicalTrials.gov NCT03180840 · fetched Nov 12, 2026
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionPHASE3 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02795676 · fetched Nov 12, 2026
- Extension Study of PRX-102 for up to 60 MonthsPHASE1_PHASE2 · COMPLETED · started Jan 16, 2014ClinicalTrials.gov NCT01981720 · fetched Nov 12, 2026
- Dose-ranging Study of PRX-102 in Adult Fabry Disease PatientsPHASE1_PHASE2 · COMPLETED · started Oct 1, 2012ClinicalTrials.gov NCT01678898 · fetched Nov 12, 2026